HCPLive Network

New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Click here to view this article.


Further Reading
Results of a multinational phase III clinical trial involving women with breast cancer in 27 countries found that adjuvant therapy with the aromatase inhibitor letrozole following surgical excision conferred greater survival benefit than tamoxifen.
Results of a multinational phase III clinical trial involving women with breast cancer in 27 countries found that adjuvant therapy with the aromatase inhibitor letrozole following surgical excision conferred greater survival benefit than tamoxifen.
Multiple studies presented at the San Antonio Breast Cancer Symposium report encouraging findings on the role of aromatase inhibitors in treating postmenopausal women with early-stage estrogen receptor-positive breast cancer.
Multiple studies presented at the San Antonio Breast Cancer Symposium report encouraging findings on the role of aromatase inhibitors in treating postmenopausal women with early-stage estrogen receptor-positive breast cancer.
Although hormonal therapy with aromatase inhibitors is highly effective at preventing recurrence in menopausal women with breast cancer, several studies have shown that adherence leaves something to be desired.
New data presented at the 31st Annual San Antonio Breast Cancer Symposium suggest that estrogen therapy may be beneficial to controlling metastatic breast cancer.
The increased risk of breast cancer among users of hormone replacement therapy varies by race/ethnicity, body mass index, and breast density, according to a study published online Sept. 3 in the Journal of the National Cancer Institute.
More Reading